Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis

Kusamori, Kosuke; Katsumi, Hidemasa; Abe, Mari; Ueda, Asuka; Sakai, Ryota; Hayashi, Ryosuke; Hirai, Yasuaki; Quan, Ying‐Shu; Kamiyama, Fumio; Sakane, Toshiyasu; Yamamoto, Akira

doi:10.1002/jbmr.147

Cited by 42 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is indicated that the transdermal permeation of ALD using this patch system was sufficient for the treatment of bone diseases. The plasma calcium level was effectively reduced after application of the ALD patch in 1a-hydroxyvitamin D 3 -induced hypercalcemia model rats (Kusamori et al, 2010). These results indicated that the developed transdermal delivery system of ALD is a promising approach that would improve therapeutic effects and better compliance and QOL (quality of life) in patients undergoing treatment for OP.…”

Section: Transdermal Delivery (Td)mentioning

confidence: 74%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Transdermal Delivery (Td)mentioning

confidence: 74%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Biophophonates are carbon-substituted pyrophosphate analogues that exhibit high affinity for hydroxyapatite, inhibit bone resorption, and used in the treatment and prevention of bone disease [49]. Alendronate sodium, a nitrogen-containing bisphosphonate, is widely used for the prevention and treatment of osteoporosis.…”

Section: The Biomarkers and Their Potential Values In Osteoporosismentioning

confidence: 99%

Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research

Jiang

Guan

et al. 2016

IJMS

View full text Add to dashboard Cite

Osteoporosis is a progressive skeletal disorder characterized by low bone mass and increased risk of fracture in later life. The incidence and costs associated with treating osteoporosis cause heavy socio-economic burden. Currently, the diagnosis of osteoporosis mainly depends on bone mineral density and bone turnover markers. However, these indexes are not sensitive and accurate enough to reflect the osteoporosis progression. Metabolomics offers the potential for a holistic approach for clinical diagnoses and treatment, as well as understanding of the pathological mechanism of osteoporosis. In this review, we firstly describe the study subjects of osteoporosis and bio-sample preparation procedures for different analytic purposes, followed by illustrating the biomarkers with potentially predictive, diagnosis and pharmaceutical values when applied in osteoporosis research. Then, we summarize the published metabolic pathways related to osteoporosis. Furthermore, we discuss the importance of chronological data and combination of multi-omics in fully understanding osteoporosis. The application of metabolomics in osteoporosis could provide researchers the opportunity to gain new insight into the metabolic profiling and pathophysiological mechanisms. However, there is still much to be done to validate the potential biomarkers responsible for the progression of osteoporosis and there are still many details needed to be further elucidated.

show abstract

“…Transversely cut tracheae were repaired with surgical sutures after a single intrapulmonary administration. The tibia bone structures of these rats under pentobarbital anesthesia were evaluated by X‐ray microcomputed tomography (µCT) (Rigaku, Tokyo, Japan) 8 weeks after the OVX operation; µCT was performed as described previously 22…”

Section: Methodsmentioning

confidence: 99%